Key Takeaways
- Eli Lilly shares surged approximately 6% on June 26 following a favorable European Medicines Agency opinion for Jaypirca in chronic lymphocytic leukemia
- A new Medicare GLP-1 Bridge initiative launching July 1 will provide Zepbound and Foundayo access for just $50 per month
- Leerink Partners upgraded its LLY price target to $1,232 in response to recent developments
- The stock climbed 9.62% during the week and reached a fresh 52-week peak of $1,206
- An early-stage trial testing abemaciclib combined with darolutamide for prostate cancer was discontinued ahead of schedule
Shares of Eli Lilly experienced a remarkable week of gains. Multiple regulatory achievements and clinical program announcements propelled LLY higher by 9.62% across a seven-day period, culminating in a new 52-week peak of $1,206.
The most significant daily advance occurred on June 26, when the pharmaceutical giant’s shares climbed roughly 6%. This rally was triggered by the European Medicines Agency’s Committee for Medicinal Products for Human Use issuing a favorable recommendation for Jaypirca (pirtobrutinib) as a treatment option for chronic lymphocytic leukemia.
When the EMA committee delivers a positive opinion, European Commission authorization typically follows within approximately two months. Since Jaypirca has already secured FDA clearance in the United States, European approval would unlock access to another substantial commercial market.
In response to these developments, Leerink Partners analysts elevated their price target for LLY shares to $1,232.
New Medicare Initiative Boosts Weight-Loss Drug Access
Complementing the cancer drug developments, Medicare unveiled a new GLP-1 Bridge initiative scheduled to begin July 1, 2026. This program will provide qualified participants with Lilly’s weight management medications Zepbound and Foundayo at a monthly copayment of just $50.
This represents a substantial cost reduction for numerous patients and has the potential to significantly increase prescription volumes. Expanding affordability and availability of GLP-1 therapies has been a critical focus for investors monitoring Lilly’s obesity treatment portfolio.
The timing of both the European regulatory news and the Medicare program announcement on the same day provided investors with dual catalysts for purchasing shares.
Clinical Development Progress Spans Multiple Disease Areas
Beyond these immediate catalysts, Lilly provided updates on a pair of Phase 3 clinical trials evaluating donanemab for Alzheimer’s disease. One study is assessing the therapy in preclinical Alzheimer’s patients within China. The second trial is investigating whether annual dosing schedules can maintain therapeutic benefits in previously responsive patients.
The pharmaceutical company also initiated a Phase 3 clinical trial examining orforglipron, an oral GLP-1 medication, for pediatric patients with Type 2 diabetes. This move extends its metabolic disease development efforts beyond adult populations.
Not all updates delivered positive news. A Phase 1b investigation combining abemaciclib with darolutamide for metastatic castration-resistant prostate cancer was halted prematurely, representing a disappointment in that particular oncology indication. However, investors appeared to overlook this setback given the breadth of positive pipeline momentum elsewhere.
Earlier this month, Lilly revealed encouraging Phase 3 results for retatrutide, its next-generation obesity medication that targets three hormone receptors simultaneously — GIP, GLP-1, and glucagon. These findings were unveiled at the American Diabetes Association’s 86th Scientific Sessions on June 6 and subsequently published in The Lancet. Previous Phase 3 data demonstrated 24.2% weight reduction at 72 weeks in cardiovascular disease patients and 28.7% weight loss in individuals with knee osteoarthritis.
LLY has gained 11.7% year-to-date. Analysts on Wall Street maintain a consensus “Strong Buy” recommendation on the shares. At Friday’s market close, Lilly reached $1,206 per share — establishing a new 52-week record high.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
